GeneStrat (Biodesix Inc.)

HAYES, Inc
Record ID 32018000083
English
Authors' recommendations: Molecular profiling is used for patients with advanced non-small cell lung cancer (NSCLC) to characterize oncogenic drivers and mechanisms of resistance to help guide appropriate treatment selection. Testing is frequently performed at diagnosis and at disease progression, as the majority of patients will develop resistance to initial treatment within 1 year of initiation. Molecular profiling has usually been performed on tissue biopsy samples. However, these samples can be challenging to obtain, may be associated with adverse events, and may not completely represent the full tumor profile due to clonal heterogeneity. In addition, biopsies can be expensive and it can take several weeks to obtain results, potentially delaying treatment. Therefore, sampling from various bodily fluids (called "liquid biopsy") is being offered to more easily and serially detect molecular alterations during treatment. This report reviews 1 such molecular profiling test, GeneStrat, which uses plasma from a patient blood sample to analyze cell-free DNA (cfDNA) and RNA for specific variants.
Details
Project Status: Completed
Year Published: 2017
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Biopsy
  • Carcinogenesis
  • Carcinoma, Non-Small-Cell Lung
  • Cell-Free Nucleic Acids
  • Disease Progression
  • Humans
  • Liquid Biopsy
  • Lung Neoplasms
  • Oncogenes
  • RNA
  • Specimen Handling
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.